Damrose E J, Damrose J F
Department of Otolaryngology, Head and Neck Surgery, Stanford University Medical Center, Stanford, CA 94305, USA.
J Laryngol Otol. 2008 Aug;122(8):824-8. doi: 10.1017/S0022215107000710. Epub 2007 Oct 2.
This study evaluated the role of botulinum toxin type A in the treatment of refractory laryngeal granulomas.
Retrospective clinical review at a tertiary care hospital. Seven patients with vocal process granulomas underwent percutaneous injection of botulinum toxin into both vocal folds, performed in an office setting. Total doses ranged from 10 to 25 U, divided between both vocal folds.
All patients experienced resolution of their granulomas over two to seven weeks. No patient developed aspiration pneumonia. All patients experienced hoarseness secondary to the injections, but voice quality returned to baseline in all patients as the toxin was degraded.
Botulinum toxin is safe and effective therapy in resolving vocal process granulomas in patients refractory to traditional therapy. The optimal treatment dose remains to be determined.
Percutaneous botulinum toxin injection is helpful in resolving laryngeal granulomas.
本研究评估了A型肉毒杆菌毒素在治疗难治性喉肉芽肿中的作用。
在一家三级医疗中心进行的回顾性临床研究。7例声带突肉芽肿患者在门诊环境下接受了经皮向双侧声带注射肉毒杆菌毒素治疗。总剂量为10至25单位,双侧声带均分。
所有患者的肉芽肿在两至七周内均消退。无患者发生吸入性肺炎。所有患者均因注射出现声音嘶哑,但随着毒素降解,所有患者的嗓音质量均恢复至基线水平。
肉毒杆菌毒素是治疗传统治疗无效的声带突肉芽肿患者的安全有效疗法。最佳治疗剂量仍有待确定。
经皮注射肉毒杆菌毒素有助于解决喉肉芽肿问题。